Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

61. Maintenance of Remission with Etanercept–DMARD Combination Therapy Compared with DMARDs Alone in African and Middle Eastern Patients with Active Rheumatoid Arthritis

Maintenance of Remission with Etanercept–DMARD Combination Therapy Compared with DMARDs Alone in African and Middle Eastern Patients with Active Rheumatoid Arthritis Maintenance of Remission with Etanercept–DMARD Combination Therapy Compared with DMARDs Alone in African and Middle Eastern Patients with Active Rheumatoid Arthritis | SpringerLink This service is more advanced with JavaScript available, learn more at Advertisement Hide Search SpringerLink June 2018 , Volume 5, , pp 149–158 (...) | Maintenance of Remission with Etanercept–DMARD Combination Therapy Compared with DMARDs Alone in African and Middle Eastern Patients with Active Rheumatoid Arthritis Authors Hassan Bassiouni Catherine Elizabeth Spargo Bonnie Vlahos Heather E. Jones Ron Pedersen Khalid Shirazy Open Access Original Research First Online: 26 February 2018 701 Downloads Abstract Introduction To compare etanercept (ETN) and placebo (PBO) for maintaining low disease activity (LDA) achieved with ETN in patients with rheumatoid

Rheumatology and therapy2018 Full Text: Link to full Text with Trip Pro

62. Real-World Treatment Patterns for Golimumab and Concomitant Medications in Japanese Rheumatoid Arthritis Patients

Real-World Treatment Patterns for Golimumab and Concomitant Medications in Japanese Rheumatoid Arthritis Patients Real-World Treatment Patterns for Golimumab and Concomitant Medications in Japanese Rheumatoid Arthritis Patients | SpringerLink This service is more advanced with JavaScript available, learn more at Advertisement Hide Search SpringerLink June 2018 , Volume 5, , pp 185–201 | Real-World Treatment Patterns for Golimumab and Concomitant Medications in Japanese Rheumatoid Arthritis (...) Patients Authors Masateru Okazaki Hisanori Kobayashi Yutaka Ishii Masayoshi Kanbori Tsutomu Yajima Open Access Original Research First Online: 22 February 2018 1.1k Downloads Abstract Introduction The aim of this study was to investigate real-world treatment patterns for use of golimumab and concomitant medications in Japanese patients with rheumatoid arthritis. Methods This study was a post hoc retrospective analysis from post-marketing surveillance data on 2350 Japanese patients with moderate/severe

Rheumatology and therapy2018 Full Text: Link to full Text with Trip Pro

63. Cost of Depression in Japanese Patients with Rheumatoid Arthritis: Evidence from Administrative Data

Cost of Depression in Japanese Patients with Rheumatoid Arthritis: Evidence from Administrative Data ORIGINAL RESEARCH Cost of Depression in Japanese Patients with Rheumatoid Arthritis: Evidence from Administrative Data Florent Guelfucci . Yuko Kaneko . Jo ¨rg Mahlich . Rosarin Sruamsiri Received: December 5, 2017 / Published online: February 22, 2018 The Author(s) 2018. This article is an open access publication ABSTRACT Introduction: To determine the cost of depres- sion comorbidity among (...) Japanese adults with rheumatoid arthritis (RA). Methods: A retrospective database study of 8968 patients diagnosed with RA between 2010 and 2015 and treated with any RA medication was conducted. Health care utilization charac- teristics were compared between patients with and without a comorbidity of depression. Propensity score matching was applied to ensure a balanced comparison between the two cohorts. Results: The prevalence of a depression comorbidity was found for 5% of the total RA patients

Rheumatology and therapy2018 Full Text: Link to full Text with Trip Pro

64. Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis

Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis | SpringerLink This service is more advanced with JavaScript available, learn more at Advertisement Hide Search SpringerLink June 2018 , Volume 5, , pp 283–291 | Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis Authors Stanley Cohen Jeffrey R. Curtis (...) Ryan DeMasi Yan Chen Haiyun Fan Arif Soonasra Roy Fleischmann Open Access Brief Report First Online: 22 February 2018 2.4k Downloads Abstract Introduction Post-marketing surveillance (PMS) is an integral part of monitoring adverse events (AEs) following approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). An analysis of PMS reports was conducted to evaluate the safety of tofacitinib in a post-marketing setting. Methods Worldwide

Rheumatology and therapy2018 Full Text: Link to full Text with Trip Pro

65. Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis

Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis DOI: 10.5152/eurjrheum.2018.17113 Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis Introduction Rheumatoid arthritis (RA) is a common chronic inflammatory disease, affecting an estimated 1 million adults in the United States (1). RA progresses to permanent disability without intervention. However, early diag- nosis and treatment reduces symptoms (...) in patients who Emily Harris 1 , Bernard Ng 2 Original Article Abstract Objective: Our study aims to determine whether the use of subcutaneous methotrexate (SC MTX) is associated with prolonged MTX use and lower incidence of hepatotoxicity in rheumatoid arthritis (RA) patients on MTX monotherapy and multiple drug therapy. Methods: We conducted a retrospective cohort study using national databases of a large hospital sys- tem. Subjects had been diagnosed with RA and treated with MTX between September 30

European journal of rheumatology2018 Full Text: Link to full Text with Trip Pro

66. Hemophagocytic lymphohistiocytosis after certolizumab treatment in a patient with rheumatoid arthritis

Hemophagocytic lymphohistiocytosis after certolizumab treatment in a patient with rheumatoid arthritis 30071926 2018 11 14 2147-9720 5 3 2018 Sep European journal of rheumatology Eur J Rheumatol Hemophagocytic lymphohistiocytosis after certolizumab treatment in a patient with rheumatoid arthritis. 203-205 10.5152/eurjrheum.2018.17108 Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening syndrome that may be triggered by hereditary factors, autoimmune and immunologic disorders (...) Blood Cancer. 2007 Feb;48(2):124-31 16937360 Arthritis Rheum. 2003 Oct 15;49(5):633-9 14558048 Clin Rheumatol. 2009 Dec;28(12):1449-52 19727917 Inflamm Bowel Dis. 2013 Jan;19(1):E4-6 22127817 Intern Med. 2012;51(6):655-7 22449679 JAMA Dermatol. 2014 Sep;150(9):1021-3 25029560 Br J Dermatol. 2010 Mar;162(3):547-53 19818067 J Rheumatol. 2004 Mar;31(3):623; author reply 623-4 14994420 Rheumatology (Oxford). 2007 Oct;46(10):1621-2 17726035 J Blood Med. 2014 Jun 12;5:69-86 24966707 Intern Med. 2011;50(17

European journal of rheumatology2018 Full Text: Link to full Text with Trip Pro

67. Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies

Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies Repository corticotropin injection in patients with rheumatoid arthrit | OARRR Javascript is currently disabled in your browser. Several features of this site will not function whilst javascript is disabled. open access to scientific and medical research Journal Email Alerts About Dove Press Open access peer-reviewed scientific and medical journals. Open Access Dove Medical Press is a member (...) of the OAI. Reprints Bulk reprints for the pharmaceutical industry. Favored Authors We offer real benefits to our authors, including fast-track processing of papers. Promotional Article Monitoring Register your specific details and specific drugs of interest and we will match the information you provide to articles from our extensive database and email PDF copies to you promptly. Social Media Back to » » Original Research Repository corticotropin injection in patients with rheumatoid arthritis resistant

Open access rheumatology : research and reviews2018 Full Text: Link to full Text with Trip Pro

68. Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis

Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis | SpringerLink This service is more advanced with JavaScript available, learn more at Advertisement Hide Search SpringerLink June 2018 , Volume 5, , pp 203–214 | Effect (...) of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis Authors Roy Fleischmann Jürgen Wollenhaupt Stanley Cohen Lisy Wang Haiyun Fan Vara Bandi John Andrews Liza Takiya Eustratios Bananis Michael E. Weinblatt Open Access Original Research First Online: 07 February 2018 1.4k Downloads Abstract Introduction Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We evaluated

Rheumatology and therapy2018 Full Text: Link to full Text with Trip Pro

69. Tofacitinib (Xeljanz) - In combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis

Tofacitinib (Xeljanz) - In combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis

Scottish Medicines Consortium2018

70. [Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report]

[Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report] Leitliniensynopse für ein DMP rheumatoide arthritis: rapid report; auftrag V17-01 [Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report] Leitliniensynopse für ein DMP rheumatoide arthritis: rapid report; auftrag V17-01 [Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Leitliniensynopse für ein DMP rheumatoide arthritis: rapid report; auftrag V17-01. [Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG

Health Technology Assessment (HTA) Database.2018

71. [Tofacitinib (rheumatoid arthritis) - addendum to commission A17-18]

[Tofacitinib (rheumatoid arthritis) - addendum to commission A17-18] Tofacitinib (rheumatoide arthritis): addendum zum auftrag A17-18; auftrag A17-4 [Tofacitinib (rheumatoid arthritis) - addendum to commission A17-18] Tofacitinib (rheumatoide arthritis): addendum zum auftrag A17-18; auftrag A17-4 [Tofacitinib (rheumatoid arthritis) - addendum to commission A17-18] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Tofacitinib (rheumatoide arthritis): addendum zum auftrag A17-18; auftrag A17-4. [Tofacitinib (rheumatoid arthritis) - addendum to commission A17-18] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 545. 2017 Final publication URL Indexing Status

Health Technology Assessment (HTA) Database.2018

72. [Sarilumab (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V]

[Sarilumab (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V] Sarilumab (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-39 [Sarilumab (rheumatoid arthritis) – benefit assessment according to §35a Social Code Book V] Sarilumab (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-39 [Sarilumab (rheumatoid arthritis) – benefit assessment according to §35a Social Code Book V] Institut für (...) Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sarilumab (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-39. [Sarilumab (rheumatoid arthritis) – benefit assessment according to §35a

Health Technology Assessment (HTA) Database.2018

73. [Baricitinib (rheumatoid arthritis) - addendum to commission A17-14]

[Baricitinib (rheumatoid arthritis) - addendum to commission A17-14] Baricitinib (rheumatoideaArthritis): addendum zum auftrag A17-14; auftrag A17-36 [Baricitinib (rheumatoid arthritis) - addendum to commission A17-14] Baricitinib (rheumatoideaArthritis): addendum zum auftrag A17-14; auftrag A17-36 [Baricitinib (rheumatoid arthritis) - addendum to commission A17-14] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Baricitinib (rheumatoideaArthritis): addendum zum auftrag A17-14; auftrag A17-36. [Baricitinib (rheumatoid arthritis) - addendum to commission A17-14] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 531. 2017 Final publication URL Indexing

Health Technology Assessment (HTA) Database.2018

74. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis

Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis 29247149 2017 12 16 0315-162X 2017 Dec 15 The Journal of rheumatology J. Rheumatol. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis. jrheum.161539 10.3899/jrheum.161539 To evaluate the longterm (...) efficacy and safety of subcutaneous tocilizumab (TCZ-SC) every 2 weeks (q2w) over 2 years in patients with rheumatoid arthritis who have an inadequate response to disease-modifying antirheumatic drugs (DMARD). Patients (n = 656) were randomized 2:1 to TCZ-SC 162 mg q2w or placebo-SC q2w plus DMARD. After a 24-week double-blind period, patients (n = 457) were rerandomized to open-label TCZ-SC q2w by means of prefilled syringe or autoinjector. Escape therapy with weekly TCZ-SC was available for patients

EvidenceUpdates2018

75. Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial

Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial 29343509 2018 02 07 1468-2060 2018 Jan 17 Annals of the rheumatic diseases Ann. Rheum. Dis. Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. annrheumdis-2017-212478 10.1136/annrheumdis-2017 (...) -212478 To evaluate the efficacy, biological activity and safety of tregalizumab in patients with active rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX). 321 patients were randomised (1:1:1:1) to placebo or tregalizumab 25, 100 or 200 mg once-weekly subcutaneously in addition to MTX treatment. Responders at week 12 continued the same treatment, and non-responders at week 12 were escalated to the next higher tregalizumab dose level or re-randomised from placebo to active

EvidenceUpdates2018

76. A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment

A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment DOI: 10.5152/eurjrheum.2018.17147 A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment Introduction The recommendations of the treatment of rheumatoid arthritis (RA) and the usage of methotrexate (MTX) as an anchor agent have been well established (1). In combination, MTX with biological (...) baseline factors and depression remission after a 6-month biological disease-modifying antirheumatic drugs (bDMARDs) treatment in rheumatoid arthritis (RA) patients. Methods: The study was conducted in 152 RA patients treated with bDMARDs. The following patient’s characteristics were studied: gender, age, disease duration, baseline prednisolone dosage, and serum matrix metalloproteinase3 (MMP3) levels. For assessment, we used the simple disease activity index (SDAI) for RA disease activity, Health

European journal of rheumatology2018 Full Text: Link to full Text with Trip Pro

77. Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression?

Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression? DOI: 10.5152/eurjrheum.2018.17021 Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression? Introduction In rheumatoid arthritis (RA) patients, there are various complications. Depression is the most common complication of RA, constituting approximately 15% of all complications (1). The odds ratio of depression in RA patients is 1.42 (...) , Tsuyoshi Kasama 1 , Kenji Sanada 2 Original Article Abstract Objective: The objective of this study was to investigate the factors associated with depression, in- cluding serum oxytocin (OXT) levels, disease activity, activities of daily living (ADL), and quality of life (QOL), and their effects on rheumatoid arthritis (RA). Methods: This study included 42 RA patients who received treatment with a biological agent. We measured the following variables before and after 6 months of treatment: baseline

European journal of rheumatology2018 Full Text: Link to full Text with Trip Pro

78. Rheumatoid arthritis

Rheumatoid arthritis Rheumatoid arthritis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Rheumatoid arthritis Last reviewed: August 2018 Last updated: September 2018 Summary A chronic, erosive arthritis that requires early and aggressive treatment. Diagnosed clinically. Laboratory and radiographic testing provide prognostic information more often than diagnostic information. Methotrexate is the anchor drug (...) for the treatment of RA. Disease activity scores (e.g., 28-joint count version of disease activity score [DAS28], clinical disease activity index [CDAI], simplified disease activity index [SDAI], routine assessment patient index data [RAPID3]) are used routinely to provide optimum care for RA patients. Definition Rheumatoid arthritis (RA) is a chronic inflammatory condition affecting around 1% of the population, making it the most common inflammatory arthritis seen by physicians. Lee DM, Weinblatt ME

BMJ Best Practice2018

80. Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries

Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries 29149289 2017 11 17 1462-0332 2017 Nov 14 Rheumatology (Oxford, England) Rheumatology (Oxford) Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries. 10.1093/rheumatology/kex394 To investigate whether patients with RA enrolled in randomized controlled trials (RCTs) and observational studies may differ in terms (...) observational studies randomized controlled trials rheumatoid arthritis rituximab tocilizumab 2017 05 05 2017 11 18 6 0 2017 11 18 6 0 2017 11 18 6 0 aheadofprint 29149289 4629381 10.1093/rheumatology/kex394

EvidenceUpdates2018